Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Emily J. Faivre(AbbVie (United States)), Yu Shen(University of Florida), Sanjay C. Panchal(AbbVie (United States)), Daniel H. Albert(AbbVie (United States)), Lisa Hasvold(AbbVie (United States)), Lloyd T. Lam(National Institutes of Health), Keith F. McDaniel(AbbVie (United States)), Tamar Uziel(AbbVie (United States)), Chang H. Park(AbbVie (United States)), Joshua P. Plotnik(AbbVie (United States)), Dachun Liu(Kunming University of Science and Technology), Srinivasa R. Mantena(AbbVie (United States)), Vasudha Sehgal(AbbVie (United States)), Stacey Fossey(AbbVie (United States)), George S. Sheppard(AbbVie (United States)), Gaurav Mehta(AbbVie (United States)), Paul Hessler(AbbVie (United States)), Warren M. Kati(AbbVie (United States)), Kenton L. Longenecker(AbbVie (United States)), John K. Pratt(AbbVie (United States)), Xiaoyu Lin(AbbVie (United States)), Le Wang(AbbVie (United States)), Lu Zhang(AbbVie (United States)), Xiaoli Huang(Sichuan Agricultural University), Xin Lü(AbbVie (United States)), Maricel Torrent(United States Military Academy), Mai H. Bui(AbbVie (United States)), Steve Fidanze(AbbVie (United States)), L. Bigelow(AbbVie (United States)), John Nicolette(AbbVie (United States)), Saul H. Rosenberg(Abbott Fund), Chaohong Sun(AbbVie (United States)), Denise Wilcox(Abbott (United States)), Richard J. Bellin(AbbVie (United States))
Cited by 404
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Requirement of the MRN complex for ATM activation by DNA damage
|The EMBO Journal|2003|1.1k
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
|Proceedings of the National Academy of Sciences|2008|985